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Abstract
Following an application from Food for Health Ireland (FHI), submitted for authorisation of a health
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of
Ireland, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an
opinion on the scientiﬁc substantiation of a health claim related to FHI LFC24, a bovine milk-derived
casein hydrolysate, and a reduction of post-prandial blood glucose responses. The food, FHI LFC24,
which is the subject of the health claim, is sufﬁciently characterised. The claimed effect proposed by
the applicant is that FHI LFC24, when co-ingested with carbohydrates, reduces post-prandial blood
glucose responses. The target population proposed by the applicant is the healthy adult population. In
view of the proposed mechanism by which the food would exert the claimed effect, i.e. ‘by increased
post-prandial insulin secretion’, the applicant was requested to provide evidence that a reduction of
post-prandial blood glucose responses achieved by an increase in insulin secretion is a beneﬁcial
physiological effect for the target population, i.e. the healthy adult population. The evidence provided
by the applicant did not establish that a reduction in post-prandial glycaemic responses achieved by an
increase in insulin secretion is a beneﬁcial physiological effect for the target population. The
Panel considers that a cause and effect relationship has not been established between the
consumption of the food, FHI LFC24, and a beneﬁcial physiological effect for the target population.
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of European Food Safety Authority.
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Summary
Following an application from Food for Health Ireland (FHI), submitted for authorisation of a health
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of
Ireland, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an
opinion on the scientiﬁc substantiation of a health claim related to FHI LFC24, a bovine milk-derived
casein hydrolysate, and a reduction of post-prandial blood glucose responses.
The scope of the application was proposed to fall under a health claim based on newly developed
scientiﬁc evidence. The application included a request for the protection of proprietary data.
The approach of the NDA Panel for the evaluation of the health claim is outlined in the European
Food Safety Authority (EFSA) general guidance for stakeholders on health claim applications and the
guidance on the scientiﬁc requirements for health claims related to appetite ratings, weight
management and blood glucose concentrations.
The food that is the subject of the health claim is FHI LFC24, which is a bovine milk-derived casein
hydrolysate. The starting material for the hydrolysate is sodium caseinate, which is subjected to
processing including enzymatic hydrolysis. The Panel considers that the food, FHI LFC24, is sufﬁciently
characterised.
The claimed effect proposed by the applicant is that FHI LFC24, when co-ingested with
carbohydrates, reduces post-prandial blood glucose responses. The target population proposed by the
applicant is the healthy adult population.
The applicant indicated that the mechanism by which the food exerts the claimed effect is by
‘increased post-prandial insulin secretion’. In view of the mechanism proposed, the applicant was
requested to provide evidence that a reduction of post-prandial blood glucose responses achieved by
an increase in insulin secretion is a beneﬁcial physiological effect for the target population, i.e. the
healthy adult population.
In reply, the applicant focussed on the safety of the food, i.e. elaborated on the differences
between the food and antidiabetic drugs (such as sulfonylureas). The applicant stated that owing to
distinct mechanisms of action, the risks (i.e. hypoglycaemia and b-cell exhaustion) associated with the
use of sulfonylureas would not pertain to the milk-protein hydrolysate (i.e. FHI LFC24). However, the
applicant did not provide evidence that a reduction of post-prandial blood glucose responses achieved
by an increase in insulin secretion is beneﬁcial for the healthy adult population, i.e. the target
population for the claim.
The Panel notes that the evidence provided by the applicant does not establish that a reduction in
post-prandial glycaemic responses achieved by an increase in insulin secretion is a beneﬁcial
physiological effect for the target population.
The Panel considers that a cause and effect relationship has not been established between the
consumption of the food, FHI LFC24, and a beneﬁcial physiological effect for the target population.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health) which are based on newly developed
scientiﬁc evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: FHI LFC24, a bovine milk-derived
casein hydrolysate, and a reduction of post-prandial blood glucose responses.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of FHI LFC24, a positive assessment of its safety, nor a decision on whether FHI LFC24 is,
or is not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
Food/constituent as stated by the applicant:
• According to the applicant, the food which is the subject of the claim is a bovine milk-derived
casein hydrolysate designated as FHI LFC24.
Health relationship as claimed by the applicant:
• According to the applicant, the co-ingestion of FHI LFC24 with carbohydrates results in a
signiﬁcant reduction in post-prandial plasma glucose concentrations. The applicant indicated
that the mechanism through which this is achieved is by increased post-prandial insulin
secretion.
Wording of the health claim as proposed by the applicant:
• ‘FHI LFC24 helps to regulate blood glucose levels following food consumption’.
Speciﬁc conditions of use as proposed by the applicant:
• According to the applicant, 12 g of FHI LFC24 should be dissolved in 120 mL of mineral water.
This beverage should then be consumed with a meal.
• The target population proposed by the applicant is the healthy adult population.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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2.1.2. Data provided by the applicant
Health claim application on FHI LFC24, a bovine milk-derived casein hydrolysate, and a reduction of
post-prandial blood glucose responses pursuant to Article 13.5 of Regulation 1924/2006, presented in
a common and structured format as outlined in the Scientiﬁc and technical guidance for the
preparation and presentation of applications for authorisation of health claims (EFSA NDA Panel,
2011).
As outlined in the general guidance for stakeholders on health claim applications (EFSA NDA Panel,
2016), it is the responsibility of the applicant to provide the totality of the available evidence.
This health claim application includes a request for the protection of proprietary data (Food for
Health Ireland, Studies 1–5, all ﬁve studies unpublished), in accordance with Article 21 of Regulation
(EC) No 1924/2006.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientiﬁc requirements for health claims related to appetite ratings, weight management and
blood glucose concentrations are outlined in a speciﬁc EFSA guidance (EFSA NDA Panel, 2012).
3. Assessment
3.1. Characterisation of the food/constituent
The food that is the subject of the health claim is FHI LFC24, which is a bovine milk-derived casein
hydrolysate.
The starting material for the hydrolysate is sodium caseinate, which is subjected to processing
including enzymatic hydrolysis. An overview of the manufacturing process was provided.
The amino acid composition, proximate analysis, molecular mass distribution proﬁle, molecular
weight distribution of the peptides and degree of hydrolysis of FHI LFC24 were provided.
Information on the stability of the food and results of batch-to-batch analyses were provided.
The Panel considers that the food, FHI LFC24, a bovine milk-derived casein hydrolysate, which is
the subject of the health claim, is sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is that FHI LFC24, when co-ingested with
carbohydrates, reduces post-prandial blood glucose responses. The target population proposed by the
applicant is the healthy adult population.
The applicant indicated that the mechanism by which the food exerts the claimed effect is by
‘increased post-prandial insulin secretion’. In view of the mechanism proposed, the applicant was
requested to provide evidence that a reduction of post-prandial blood glucose responses achieved by
an increase in insulin secretion is a beneﬁcial physiological effect for the target population, i.e. the
healthy adult population.
In reply, the applicant focussed on the safety of the food, i.e. elaborated on the differences
between the food and antidiabetic drugs (such as sulfonylureas). The applicant stated that owing to
distinct mechanisms of action, the risks (i.e. hypoglycaemia and b-cell exhaustion) associated with the
use of sulfonylureas would not pertain to the milk-protein hydrolysate (i.e. FHI LFC24). However, the
applicant did not provide evidence that a reduction of post-prandial blood glucose responses achieved
by an increase in insulin secretion is beneﬁcial for the healthy adult population, i.e. the target
population for the claim.
The Panel notes that the evidence provided by the applicant does not establish that a reduction in
post-prandial glycaemic responses achieved by an increase in insulin secretion is a beneﬁcial
physiological effect for the target population.
The Panel considers that a cause and effect relationship has not been established between the
consumption of the food, FHI LFC24, and a beneﬁcial physiological effect for the target population.
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4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food, FHI LFC24, a bovine milk-derived casein hydrolysate, is sufﬁciently characterised.
• The claimed effect proposed by the applicant is that FHI LFC24, when co-ingested with
carbohydrates, reduces post-prandial blood glucose responses. The target population proposed
by the applicant is the healthy adult population. The applicant indicated that the mechanism by
which the food exerts the claimed effect is by ‘increased post-prandial insulin secretion’. No
evidence was provided that a reduction in post-prandial glycaemic responses achieved by an
increase in insulin secretion is a beneﬁcial physiological effect for the target population.
• A cause and effect relationship has not been established between the consumption of the
food, FHI LFC24, and a beneﬁcial physiological effect for the target population.
Steps taken by EFSA
1) Health claim application on FHI LFC24, a bovine milk-derived casein hydrolysate, and a
reduction of post-prandial blood glucose responses pursuant to Article 13(5) of Regulation
(EC) No 1924/2006 (Claim serial No: 0444_IE). Submitted by Food for Health Ireland (FHI),
University College Dublin, Belﬁeld, Dublin 4, Ireland.
2) The application was received by EFSA on 1 December 2015.
3) The scope of the application was proposed to fall under a health claim based on newly
developed scientiﬁc evidence. The application included a request for the protection of
proprietary data.
4) The scientiﬁc evaluation procedure started on 11 January 2016.
5) On 17 March 2016, the Working Group on Claims of the NDA Panel agreed on a list of
questions for the applicant to provide additional information to accompany the application
and the scientiﬁc evaluation was suspended on 7 April 2016, in compliance with Article 18(3)
of Regulation (EC) No 1924/2006.
6) On 22 April 2016, EFSA received the applicant’s reply and the scientiﬁc evaluation was
restarted, in compliance with Article 18(3) of Regulation (EC) No 1924/2006.
7) During its meeting on 28 June 2016, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to FHI LFC24, a bovine milk-
derived casein hydrolysate, and a reduction of post-prandial blood glucose responses.
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